Otello Stampacchia, Omega
Omega Funds goes back to the well with newest $650M fund, taking a 'stage-agnostic' approach to biotech VC
Amid a very difficult back half of the year for biotech investing, some bullish investors are making the case for a major rally in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
